NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
Healthcare
$2.55 +1.43%
+$0.06 today
- Market cap
- $113.04M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
52W Low $1.62High $5.06
Volume 1.39M
Average 1.27M
Income Statement
Follow revenue through to earnings.
Revenue
$1.23M
FY 2025 · Annual
Operating Income
-$16.22M
FY 2025 · Annual
Net Income
-$28.62M
FY 2025 · Annual
Income Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | 2K | 4K | 5K | 5K | 505K |
| Gross Profit | (2K) | (4K) | (5K) | (5K) | 720K |
| Gross Margin | — | — | — | — | 58.8% |
| Research & Development | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M |
| Selling, General & Admin | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M |
| Operating Expenses | 95.2M | 44.33M | 27.58M | 19.7M | 16.94M |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| EBITDA | (93.04M) | (39.75M) | (30.03M) | (24.04M) | (27.81M) |
| EBITDA Margin | — | — | — | — | -2270.0% |
| Operating Income | (95.2M) | (44.34M) | (27.59M) | (19.7M) | (16.22M) |
| Operating Margin | — | — | — | — | -1324.4% |
| Interest Income | 18 | 249K | 494K | 44K | 12K |
| Interest Expense | 18K | 0 | 120K | 1.08M | 671K |
| Other Income / Expenses | 2.14M | 4.58M | (2.56M) | (5.42M) | (12.4M) |
| Income Before Tax | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Pre-Tax Margin | — | — | — | — | -2336.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Net Margin | — | — | — | — | -2336.5% |
| EPS (Basic) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| EPS (Diluted) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| 46.92M | 65.77M | 7.58M | 10.52M | 21.4M | |
| 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
NRXP Earnings Waterfall · TTM
NASDAQ:NRXP · Revenue to Net Income
Key Ratios
EPS$-1.28
Gross Margin29.2%
Net Margin-632.8%
P/E Ratio10.9
P/S Ratio113.8
Analysis
$2.3M of revenue converted into -$24.5M of net income for the selected period. Gross margin is 29.2% and net margin is -632.8%, showing how much revenue survives after costs and taxes. EPS is $-1.28, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| DEF 14A | DEF 14A filing | Nov 5, 2026 | |
| DEFA14A | DEFA14A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 8-K | Current report | Nov 2, 2026 |
How much revenue does NRXP generate?
NRx Pharmaceuticals, Inc. (NRXP) reported $1.23M of revenue in fiscal 2025.
Is NRXP profitable?
NRx Pharmaceuticals, Inc. (NRXP) reported -$28.62M of net income, with a net margin of -2336.5%.
Continue the stock analysis
Jump to another research area for this company.